Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
Clinical trial NCT06958484 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06958484
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-01
- Primary completion
- 2026-10-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.